Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 0.79 |
| ▸ | MTNR1B | P49286 | 20/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810063 | 1.00 | MTNR1A (0.79) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL3065294 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29237 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL338730 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL1566122 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL3069652 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2459178 | 0.81 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2459176 | 0.81 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | ON TARGET THERAPEUTICS LLC | 2019-05-09 | — | — | US | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| US-20150352038-A1 | A DOSAGE FORM FOR ADMINISTERING AN ACTIVE PRINCIPLE FOR ACCELERATED SLEEP INDUCTION AND/OR FOR TREATING SLEEP DISORDERS AND/OR FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER | ROSSELLO, Raphael (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-1100508-B8 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1100508-B1 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1100508-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-1999063977-A3 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-03-29 | — | — | WO | disclosed |
| WO-1999063977-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MTNR1A 3038/4885MTNR1B 3448/4885ABCB11 4014/4885 |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | MTNR1A 3038/4885MTNR1B 3448/4885ABCB11 4014/4885 |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | LDLR, HDLBP, LIPG | MTNR1A 3038/4885MTNR1B 3448/4885ABCB11 4014/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MTNR1A 3038/4885MTNR1B 3448/4885ABCB11 4014/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | MTNR1A 3038/4885MTNR1B 3448/4885ABCB11 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.